MX2021001595A - Uso de ligandos agonistas del receptor igf-2 para el tratamiento del sindrome de angelman y autismo. - Google Patents

Uso de ligandos agonistas del receptor igf-2 para el tratamiento del sindrome de angelman y autismo.

Info

Publication number
MX2021001595A
MX2021001595A MX2021001595A MX2021001595A MX2021001595A MX 2021001595 A MX2021001595 A MX 2021001595A MX 2021001595 A MX2021001595 A MX 2021001595A MX 2021001595 A MX2021001595 A MX 2021001595A MX 2021001595 A MX2021001595 A MX 2021001595A
Authority
MX
Mexico
Prior art keywords
igf
autism
treatment
angelman syndrome
receptor agonist
Prior art date
Application number
MX2021001595A
Other languages
English (en)
Inventor
Cristina Maria Alberini
Dirk Trauner
Christopher James Arp
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of MX2021001595A publication Critical patent/MX2021001595A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan métodos para el tratamiento de trastornos del neurodesarrollo, tales como el síndrome de Angelman y el autismo, que comprenden administrar a un individuo una composición que comprende un ligando agonista del receptor IGF 2 El ligando agonista del receptor IGF-2 puede ser IGF-2, manosa-6- fosfato o un derivado de la misma. También se describen composiciones que comprenden derivados de manosa-6-fosfato.
MX2021001595A 2018-08-10 2019-08-12 Uso de ligandos agonistas del receptor igf-2 para el tratamiento del sindrome de angelman y autismo. MX2021001595A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862717372P 2018-08-10 2018-08-10
PCT/US2019/046227 WO2020033971A1 (en) 2018-08-10 2019-08-12 Use of igf-2 receptor agonist ligands for treatment of angelman syndrome and autism

Publications (1)

Publication Number Publication Date
MX2021001595A true MX2021001595A (es) 2021-06-08

Family

ID=69415274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001595A MX2021001595A (es) 2018-08-10 2019-08-12 Uso de ligandos agonistas del receptor igf-2 para el tratamiento del sindrome de angelman y autismo.

Country Status (12)

Country Link
US (1) US20210315914A1 (es)
EP (2) EP4356964A2 (es)
JP (1) JP7466927B2 (es)
KR (1) KR20210075068A (es)
CN (1) CN113164501A (es)
AU (1) AU2019319296A1 (es)
BR (1) BR112021002456A2 (es)
CA (1) CA3109137A1 (es)
ES (1) ES2966930T3 (es)
MX (1) MX2021001595A (es)
PL (1) PL3833358T3 (es)
WO (1) WO2020033971A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4138880A2 (en) * 2020-04-24 2023-03-01 New York University Use of igf-2 for treatment of epileptic seizures

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9516012D0 (en) 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
US6093388A (en) * 1996-08-12 2000-07-25 Btg International Limited Mannose-6-phosphate composition and its use in treating fibrotic disorders
AUPO309896A0 (en) * 1996-10-18 1996-11-14 Australian National University, The Novel phosphosugars and phosphosugar-containing compounds having anti-inflammatory activity
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
GB0516722D0 (en) * 2005-08-15 2005-09-21 Cancer Rec Tech Ltd Methods and materials
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
FR2930942B1 (fr) * 2008-05-07 2011-03-04 Centre Nat Rech Scient Nouvelles utilisations de derives de d-mannopyranose activateurs de l'angiogenese
JP2012525369A (ja) * 2009-04-28 2012-10-22 ファーマキシス リミテッド 創傷および線維性障害の治療のためのホスホテトラヒドロピラン化合物
WO2011000958A1 (en) * 2009-07-03 2011-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
EP2558622A4 (en) * 2010-04-06 2013-07-24 Univ George Washington COMPOSITIONS AND METHODS FOR IDENTIFYING INTERFERENCE FROM THE AUTISM SPECTRUM
WO2013119964A2 (en) * 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
BR112015012506A2 (pt) * 2012-11-28 2017-07-11 Neuren Pharmaceuticals Ltd tratamento de transtornos do espectro do autismo usando ácido glicil-l-2-metilprolil-l-glutâmico
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
WO2017087256A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors

Also Published As

Publication number Publication date
ES2966930T3 (es) 2024-04-25
EP3833358A1 (en) 2021-06-16
CN113164501A (zh) 2021-07-23
JP2021534125A (ja) 2021-12-09
US20210315914A1 (en) 2021-10-14
JP7466927B2 (ja) 2024-04-15
AU2019319296A1 (en) 2021-03-25
BR112021002456A2 (pt) 2021-05-04
EP3833358A4 (en) 2022-04-13
CA3109137A1 (en) 2020-02-13
EP3833358B1 (en) 2023-12-06
PL3833358T3 (pl) 2024-03-04
WO2020033971A1 (en) 2020-02-13
KR20210075068A (ko) 2021-06-22
EP4356964A2 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
MY202018A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
PH12018502742A1 (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
JOP20190281A1 (ar) مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
EA201692422A1 (ru) Состав, содержащий пролекарство гемцитабина
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12018502016A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2018002906A (es) Metodos de tratamiento de trastornos del desarrollo con pipradrol.
JOP20170069B1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
EA033197B1 (ru) Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
WO2013134047A3 (en) Aminoquinoline derivatives and uses thereof
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
NZ763528A (en) Heterocyclic gpr119 agonist compounds
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
PH12017501735A1 (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same